Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ELC Group Announces Appointment of Dr. Siddharth Chachad

Published: Thursday, August 21, 2014
Last Updated: Thursday, August 21, 2014
Bookmark and Share
Internationally acclaimed clinical pharmacologist joins global regulatory affairs specialist in key management post.

ELC Group has announced the appointment of internationally acclaimed clinical pharmacologist Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs.

A member of the UK Faculty of Pharmaceutical Medicine, Dr. Chachad is an expert in the design and execution of pre-clinical and clinical development programme for drug products across dosage forms and therapeutic categories. Dr. Chachad has gained considerable career experience in the delivery medical services, medico-regulatory affairs and clinical development, and has worked across global clinical development strategy and operations of generics, new drugs and biosimilars. Dr. Siddharth’s extensive expertise covers all phases of clinical studies, including pre-clinical, pharmacodynamic studies, bioequivalence, PK in patients and full-blown clinical efficacy and safety studies.

“The appointment of Dr. Siddharth Chachad comes at a pivotal time for ELC Group,” said Marco Rubenstein, CEO of ELC Group. “Having been instrumental in the development of successful product registration strategies, I have no doubt that Dr. Siddarth will prove an exceptional leader of our Global Clinical Development and Medical Affairs team.”

Dr. Chachad added: “I am excited to be joining ELC Group and bringing my experience of Clinical Development and Medical Affairs to what is already a world-class team in this area.”

A renowned speaker at numerous clinical research and pharmacovigilance conferences, Dr. Chachad has authored over 25 publications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ELC Group Expands into Pharmaceutical Product Development Market
Fast-growing regulatory affairs provider creating extensive product portfolio for sale across US, EU, LATAM, MENA and China.
Saturday, June 13, 2015
ELC Group Signs 1.5 Million Euro Regulatory Affairs Contract
Landmark deal ELC Group’s Concept to Commercialization solution approach.
Friday, May 01, 2015
ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
Inna Demidova to head new Moscow office for fast-growing global regulatory affairs specialist.
Tuesday, July 29, 2014
ELC Group Launches Clinical Trials Services
ELC Group now offering comprehensive range of consultancy and support services for clinical trials.
Thursday, February 21, 2013
ELC GROUP Aim to Foster Strategic and Economic Ties Within India and China
Company visit to addresses regulatory challenges for 2012.
Wednesday, July 13, 2011
ELC Group Announces Doubled Revenues
Company set to increase expansion through acquisition.
Thursday, May 26, 2011
ELC GROUP Appoints Former TOPRA President
World-renowned physician Dr. Paolo Biffignandi joins ELC GROUP’s Advisory Board.
Friday, May 13, 2011
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!